On October 14, the 24th China Patent Awards Ceremony was held in Dalian.

Hansoh Pharma's invention patent for Ametinib was awarded the 'China Patent Gold Award'. The China Patent Award, jointly established by the State Intellectual Property Office and the World Intellectual Property Organization, is the highest honor in the Chinese intellectual property community. This is the second time Hansoh Pharmaceutical has won this honor.

The China Patent Award has been successfully selected for 24 times since 1989. It mainly focuses on key industries and core technologies in key fields, highlights the 'big country's important tools' in the manufacturing industry, and solves 'stuck neck' technical problems. It represents the highest technological level in the industry and is our country's knowledge An important manifestation of the achievements of a country with strong property rights.

A total of 29 invention and utility model patents were awarded the China Patent Gold Award at this conference. The invention patent 'EGFR inhibitors and their preparation and application' (patent number: ZL 201580045311.2) stood out from more than 2,400 participating patents and won the China Patent Gold Award, demonstrating the social value of Ametinib and the innovative strength of Hansoh Pharmaceuticals.

Ametinib: Small molecule meets big needs

Lung cancer is currently the cancer with the highest incidence rate in my country, and there is an urgent clinical need for third-generation EGFR-targeted drugs. Through innovative research and development, Hansoh Pharmaceutical's scientific research team has designed a new drug molecule, Ametinib, which fills the gap in my country's third-generation EGFR inhibitors, breaks the monopoly of imported drugs, and brings the world's leading treatment options to patients with non-small cell lung cancer.

As the first third-generation EGFR inhibitor in Asia and the second in the world, ametinib is used for the first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC). The two approved indications have been included in the National Reimbursement Directory, significantly reducing the risk of lung cancer. burden on patients and society.

Intellectual Property: High-value patents protect full-cycle operations

Hansoh Pharmaceutical attaches great importance to intellectual property management. The intellectual property management system passed the national standard certification in 2015. Hansoh Pharmaceutical, an important subsidiary, has been rated as a national intellectual property demonstration enterprise for many consecutive years.

The company deeply implements high-value patent cultivation and management standards, and conducts a full research and development cycle and global intellectual property layout for each innovative drug. Combining the results of innovative products at different stages of research and development, the patent management department conducts a series of patent layouts for different technical themes such as pharmaceutical compounds, pharmaceutical salt forms/crystalline forms, pharmaceutical preparations or preparation processes, and new pharmaceutical uses, and conducts a series of patent layouts on core Patents apply for diversified protection in many overseas countries. Currently, the award-winning patent for Ametinib has entered 13 countries and regions around the world, and has been authorized in China, the United States, Europe, Japan and other countries and regions.

Up to now, Hansoh Pharmaceutical has won 2 China Patent Gold Awards, 1 Silver Award and 6 Excellence Awards. The awarding of the China Patent Gold Award to Ametinib is a high recognition of the company's patent technology level and innovation capabilities by the State Intellectual Property Office and the World Intellectual Property Organization. Hansoh Pharma will continue to strengthen scientific and technological research, lead technological innovation, create a world-class advanced drug manufacturing industry highland, and contribute more to my country's high-level scientific and technological self-reliance and economic and social development.

Contact:

Tel: 0518-83096666

(C) 2023 Electronic News Publishing, source ENP Newswire